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OBJECTIVES The aim of this study was to assess the role of Wiktor stent implantation after recanalization
of chronic total coronary occlusions with regard to the clinical and angiographic outcome after
six months.
BACKGROUND Beside the common use of stents in clinical practice, the number of stent indications proven
by randomized trials is still limited.
METHODS Eighty-five patients with a thrombolysis in myocardial infarction grade 0 chronic coronary
occlusion were examined. After standard balloon angioplasty, the patients were randomly
assigned to stent implantation, or percutaneous transluminal coronary angioplasty (PTCA)
alone (no further intervention). Quantitative coronary angiography was performed at baseline
and after six months.
RESULTS The minimal lumen diameter did not differ immediately after recanalization (stent group
1.61 6 0.30 mm vs. PTCA group 1.65 6 0.36 mm), and increased after stent implantation
to 2.51 6 0.41 mm. After six months, the stent group still had a significantly greater lumen
(1.57 6 0.59 vs. 1.06 6 0.90 mm; p , 0.01) and a significantly lower restenosis and
reocclusion rate (32% and 3%) compared with the PTCA group (64% and 24%); restenosis
analysis according to treatment was 72% (PTCA) versus 29% (stent, p , 0.01). Late loss was
equal in both groups. At follow-up, the stent patients had a better angina class (p , 0.01),
and fewer cardiac events (p , 0.03). A meta-analysis including this trial and three other
controlled trials with the Palmaz-Schatz stent showed concordant results.
CONCLUSIONS Stent implantation after reopening of a chronic total occlusion provides a better angiographic
result, corresponding to a better clinical outcome with fewer recurrence of symptoms and
reinterventions after six months. (J Am Coll Cardiol 1999;34:722–9) © 1999 by the
American College of Cardiology
The long-term success after percutaneous transluminal cor-
onary angioplasty (PTCA) for chronic total occlusions is
hampered by a high rate of subacute reocclusion and late
restenosis. However, after successful recanalization of a total
occlusion (provided the vessel remains patent), the patients
had relief from symptoms, improvement of left ventricular
function, fewer cardiac events and fewer requirements for
bypass surgery (1,2). Successful primary recanalization can
be achieved in more than 70% (3,4) at low risk (5), however,
recurrence rates are as high as 77% (6). So far, stents are the
only clinically applicable tool succeeding in a remarkable
reduction of restenosis rate, as demonstrated by the Belgium
Netherlands Stent Trial (BENESTENT) and the Stent
Restenosis Study (STRESS) trials (7,8). Yet, these investi-
gations are only applicable on focal nonocclusive lesions in
patients with symptomatic single-vessel disease. Though
there are some strong suggestions that stenting in chronic
total occlusions may be useful in preventing restenosis and
reocclusion, a randomized trial was not available at the onset
of our study. Recently, three other controlled trials (9–11)
have shown a reduction of restenosis in chronic coronary
occlusions with the Palmaz-Schatz stent. The aim of the
present study was to evaluate if there is an advantage of
elective Wiktor stent implantation after successful angio-
plasty of a chronic total occlusion with regard to the clinical
and angiographic outcome after six months.
METHODS
Study design and patient selection. The SPACTO study
(Stent versus PTCA after recanalization of chronic total
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occlusions) was directed in two centers (Ulm and Go¨ttin-
gen, Germany).
From July 1994 to January 1997, a total of 223 patients
were scheduled for recanalization of a total coronary occlu-
sion and screened for this study. Patients were included if
the event causative for the occlusion occurred at least 28
days earlier, ischemia in the supplied area was proven by
either exercise electrocardiography or myocardial scintigra-
phy and online quantitative coronary angiography revealed a
reference diameter (RD) of at least 2.7 mm (for deployment
of a 3-mm stent). Total occlusion was defined as thrombol-
ysis in myocardial infarction (TIMI) grade 0 flow (12).
Exclusion criteria were the presence of any contraindica-
tions for anticoagulation with phenprocoumon, ticlopidine
or acetylsalicylic acid, renal failure and recent cerebrovascu-
lar events. The study protocol was approved by the local
ethics committee in both centers, and written informed
consent was obtained from every patient.
PTCA/stent implantation procedure and randomization.
After successful recanalization with standard balloon angio-
plasty resulting in an RD of at least 2.7 mm in on-line
quantitative coronary angiography, the patients were ran-
domly assigned either to PTCA (no further intervention) or
implantation of one or more Wiktor stents. All patients
were pretreated with at least 500 mg acetylsalicylic acid
orally or intravenously. They received a 10,000-U bolus of
heparin before recanalization adjusted by the activated
clotting time. Afterwards, they were treated with acetylsal-
icylic acid 100 mg/day throughout the study. The stent
group additionally received phenprocoumon (initial 40% of
the stented patients), or ticlopidine 2 3 250 mg/day, and
acetylsalicylic acid 300 mg/day (60% of the patients) for
three months according to recent recommendations for
poststent treatment (13). The Wiktor-GX stent (Medtron-
ics, San Diego, California) consists of a single tantalum wire
formed as a sinusoidal wave and wound into a helical coil. It
is obtainable mounted on 3-, 3.5- and 4-mm balloon
catheters. Its prominent properties are a high radio-opacity
and flexibility.
Follow-up. Coronary events during and after the proce-
dure were recorded, and exercise testing was performed after
the recanalization procedure. Clinical controls were done in
the cardiology clinic four and 12 weeks after the procedure,
including physical examination, stress test and history tak-
ing of cardiac complaints. Six months after recanalization,
the patients were hospitalized for reangiography, and again
a stress test was performed and all events were recorded. For
evaluation of cardiac symptoms, the Canadian Cardiovas-
cular Society (CCS) classification of angina (14) was used.
Coronary angiography was required six months after the
procedure. If an angiographic study was performed earlier
than six months due to recurrent symptoms and repeated
revascularization was carried out, this one was used for
quantitative coronary angiography.
Quantitative coronary angiography. The Kontron Cardio
500 system (Kontron Instruments, Tokyo, Japan) was used
for quantitative analysis. Intracoronary glyceroltrinitrate was
administered before all angiographic assessments. To assess
the minimal luminal diameter (MLD), the most severe
stenosis in two orthogonal views was measured post-
PTCA/prestent, poststent and at follow-up. The RD was
interpolated by the computer algorithm using a proximal
and a distal reference in a “normal” looking vessel area
adjacent to the stenosis. Percent stenosis was calculated as
[1 2 MLD/RD 3 100], and numerically negative stenoses
(e.g., due to stent oversizing) were counted as 0%. Biplane
left ventricular analysis was performed to assess the ejection
fraction and the ventricular size.
End points and statistics. Primary end points were resten-
osis and reocclusion rates six months after stent implanta-
tion versus conventional balloon angioplasty. Restenosis was
defined as at least 50% stenosis on the follow-up angiogram.
Major cardiac events including death (related to PTCA/
stent or heart disease), myocardial infarction, further revas-
cularization and recurrence of angina during follow-up were
considered as secondary end points.
Continuous data are presented as means 6 standard
deviation or median (range). For analysis of differences
between the two treatment groups, the two-tailed Student t
test was used in case of standard distribution (tested with
the Kolmogorov-Smirnov test); otherwise, the Mann-
Whitney U test was applied. Categorical data were com-
pared by the chi-square test. To account for differences in
angiographic baseline data, multiple analysis of covariance
was performed. Risk factor analysis for restenosis or reoc-
clusion was done by multivariate logistic regression and Cox
proportional regression. A statistical probability of p , 0.05
was considered to be significant.
Abbreviations and Acronyms
BENESTENT 5 Belgium Netherlands Stent Trial
CCS 5 Canadian Cardiovascular Society
GISSOC 5 Gruppo Italiano di Studio sullo Stent
nelle Occlusioni Coronariche
LAD 5 left anterior descending artery
MLD 5 minimal luminal diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
RCA 5 right coronary artery
RD 5 reference diameter
SICCO 5 Stenting in chronic coronary
occlusion
SPACTO 5 Stent versus PTCA after
recanalization of chronic total
occlusions
STRESS 5 Stent Restenosis Study
TIMI 5 thrombolysis in myocardial infarction
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RESULTS
Patients. Out of the 223 screened patients with chronic
total occlusions, 139 (62%) were successfully recanalized.
From these, 20 patients refused to take part in the study, 23
had a vessel size below 2.5 mm and another 11 had
contraindications against the anticoagulation protocol. Fi-
nally, 85 patients with a median age of 62 years were
randomized. There was no difference in demographic data
between the patients from Ulm and Go¨ttingen, except for
hypertension being more frequent in the Ulm subgroup
(70% vs. 38%, p 5 0.04).
Baseline characteristics of the two treatment groups are
shown in Table 1. Apart from a significantly higher rate of
women in the stent group, the PTCA and the stent group
did not differ in age, risk factors, extent of disease and
angiographic data.
Procedural outcome. From the 85 patients, 42 were ran-
domized to the stent group and 43 to the PTCA group.
There were seven crossovers with stent implantation in the
PTCA group due to dissection (n 5 2), acute vessel closure
(n 5 1) or deterioration of the initial result after random-
ization (n 5 4). Thus, a total of 49 patients received one
(69%) or multiple (31%) Wiktor stents (49% 3 mm, 24%
3.5 mm, 6% 4 mm in diameter). However, the data were
analyzed by intention to treat.
Postprocedure, all patients received antiplatelet treatment
with acetylsalicylic acid (95%) and/or ticlopidine (38%).
The patients in the stent group received ticlopidine (57% vs.
19%, p , 0.01) and phenprocoumon (43% vs. 16%, p ,
0.01) more frequently compared with the PTCA group.
Subacute stent thrombosis occurred in one case (2.4%);
this patient did not take his medication. One stent implan-
tation was unsuccessful because the stent could not be
advanced to the lesion site due to extreme vessel tortuosity.
Bleeding complications or femoral aneurysms were nonsig-
nificantly higher in the stent group (11.6%) compared with
the PTCA group (4.8%). Excluding the patients with
phenprocoumon therapy, only 5.6% of the stent patients
had a bleeding complication.
Angiographic results. Angiographic follow-up at six
months was performed in 79% of all patients. Eighteen
patients without follow-up angiography were excluded from
further analysis due to their unknown restenosis status,
although clinical follow-up was free from myocardial infarc-
tion or death.
Restenosis rate at follow-up defined as .50% stenosis
was 32.4% in the stent group and 63.6% in the PTCA group
(p 5 0.01, intention-to-treat analysis). All patients with
restenosis had an increase in percent stenosis by at least 17
percentage points. Reocclusion rate was 2.9% in the stent
group and 24.2% in the PTCA group (p 5 0.01; Fig. 1).
Analysis based on therapy received revealed an even stronger
difference: 28.9% restenosis rate in the stent group versus
72.4% (p , 0.01) in the PTCA group, and 2.6% reocclusion
in the stent group versus 27.6% (p , 0.01) in the PTCA
group. Restenosis rate in the left anterior descending artery
(LAD) occlusion subgroup was 75% with conventional
Table 1. Clinical and Angiographic Base-line Data
PTCA
(n 5 43)
Stent
(n 5 42)
Male (%) 81.4 57.1*
Age (years), median (range) 62.0 (34–76) 62.5 (36–78)
Smoking (%) 48.8 42.9
Current (%) 32.6 23.8
Diabetes (%) 32.6 35.7
Hypertension (%) 60.5 61.9
Hyperlipidaemia (%) 60.5 69.0
Body mass index 27.7 6 3.7 27.1 6 2.9
Angina class (%):
I 37.5 8.3
II 25.0 33.3
III 37.5 54.2
IV 0.0 4.2
Unstable angina (%) 7.0 11.9
Previous Q-wave infarction (%) 45.8 37.5
Myocardial infarction in
history (%)
39.5 35.7
Multiple infarctions (%) 18.6 31.0
Number of diseased
vessels (mean)
1.8 6 0.9 1.8 6 0.7
Multi vessel disease (%) 50.0 66.7
Target vessel:
LAD (n) 12 15
CX (n) 9 6
RCA (n) 22 21
Age of occlusion:
Median days (range) 65.5 (28–310) 37.5 (28–262)
Mean days 76.4 6 58.4 59.3 6 50.2
Lesion calcified (%) 41.7 54.2
*p 5 0.02. CX 5 circumflex artery; LAD 5 left anterior descending artery; PTCA 5
percutaneous transluminal coronary angioplasty; RCA 5 right coronary artery.
Figure 1. Elective implantation of the Wiktor stent after success-
ful recanalization reduced both restenosis and reocclusion rate.
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PTCA, while there was no stent-treated patient with
restenosis (p , 0.01). In the right coronary artery (RCA)
subgroup, restenosis rate was 83.3% in the PTCA group
versus 33.3% in the stent group (p , 0.01), respectively.
The results of the quantitative coronary angiography are
shown in Table 2. At randomization, RD and percent
stenosis were significantly higher in the stent group, but the
mean MLD did not differ. After stent implantation, the
MLD had significantly improved. At follow-up after six
months, the stent group still had a larger mean luminal
diameter (1.57 vs. 1.06 mm, p , 0.01). The mean reduction
in the luminal diameter during follow-up (late loss) was
equal in both groups (0.93 vs. 0.85 mm).
These data are illustrated in Figure 2. Figures 3 and 4
show the difference in MLD between the stent and the
PTCA treatment group analyzed according to treatment
(Fig. 3) and intention to treat (Fig. 4).
Multiple covariance analysis revealed that the signifi-
cantly higher MLD of the stent group at follow-up was
independent from the baseline differences of RD and/or
percent stenosis mentioned above. Subgroup analysis with
respect to the higher restenosis rate of the RCA compared
with the LAD showed no difference of the RD and MLD
at randomization. The postinterventional MLD was even
slightly higher (analysis of variance, p 5 0.094) in the RCA
(PTCA 2.01 6 0.69 mm; stent 2.55 6 0.40 mm) compared
with the LAD (PTCA 1.82 6 0.47 mm; stent 2.25 6
0.34 mm). However, in patients with stent implantation,
the mean number of stents was significantly higher in the
RCA compared with the LAD (1.9 vs. 1.1; p , 0.01).
Events and clinical outcome. Clinical follow-up data were
available from 80 of the 85 patients (94%). One asymptom-
atic patient in the stent group died from postoperative
complications after rectum cancer surgery. One additional
Table 2. Quantitative Coronary Angiography Results Analyzed by Intention to Treat and by Treatment
Intention to treat Treatment
PTCA Stent p Value PTCA Stent p Value
Reference diameter (mm):
at randomization 2.58 6 0.44 2.83 6 0.43 0.01 2.53 6 0.39 2.83 6 0.46 , 0.01
after stenting 2.65 6 0.46 2.93 6 0.50 0.03 2.53 6 0.39 2.98 6 0.48 , 0.01
at follow-up 2.78 6 0.47 2.75 6 0.48 NS 2.67 6 0.38 2.84 6 0.53 NS
difference randomization to follow-up p , 0.01 NS p , 0.01 NS
MLD (mm):
at randomization 1.65 6 0.36 1.61 6 0.30 NS 1.71 6 0.32 1.56 6 0.33 0.05
after stenting 1.89 6 0.53 2.51 6 0.41 , 0.01 1.73 6 0.33 2.56 6 0.43 , 0.01
at follow-up 1.06 6 0.90 1.57 6 0.59 , 0.01 0.88 6 0.72 1.66 6 0.67 , 0.01
difference randomization to follow-up p , 0.01 NS p , 0.01 NS
Stenosis (%):
at randomization 35.4 6 12.0 42.3 6 11.3 , 0.01 32.5 6 8.0 43.7 6 12.5 , 0.01
after stenting 29.4 6 10.9 14.6 6 10.3 , 0.01 31.7 6 9.6 14.7 6 9.9 , 0.01
at follow-up 63.2 6 28.9 43.7 6 19.2 , 0.01 67.8 6 26.1 42.3 6 20.4 , 0.01
difference randomization to follow-up p , 0.01 NS p , 0.01 NS
Late loss (mm):
at follow-up 0.85 6 0.79 0.93 6 0.71 NS 0.86 6 0.75 0.91 6 0.75 NS
Loss index:
at follow-up 0.46 6 0.41 0.36 6 0.25 NS 0.49 6 0.41 0.34 6 0.26 NS
Increase in percent stenosis:
at follow-up 35.1 6 28.5 30.2 6 23.0 NS 37.7 6 27.5 28.7 6 24.0 NS
PTCA 5 percutaneous transluminal coronary angioplasty; MLD 5 minimal luminal diameter.
Figure 2. MLD and RD analyzed according to treatment. Stent-
ing resulted in a significant improvement of acute lumen gain
(straight line with diamond). Late lumen loss did not differ with
or without stent, resulting in a significantly higher MLD of the
stent group at follow-up.
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patient in the stent group and three patients in the PTCA
group were lost to follow-up. In the stent group, there were
significantly more event-free patients with a significantly
better clinical outcome. Cardiac events analyzed by inten-
tion to treat are shown in Table 3. The higher event-free
survival of the stent group (70%) in contrast to the PTCA
group (42.5%) was also significant by solely clinical
follow-up based on anginal status and stress test (p 5
0.013).
Patients with stent had a significant greater improvement
of their CCS class angina (1.3 vs. 0.3 classes; p , 0.01; see
Fig. 5). Stress test and left ventricular function data analysis
revealed a strong tendency towards a better outcome in
patients with stent. In terms of the lower percentage of
patients with positive stress test in the stent group (40.9% vs
13.6%), this difference was statistically significant. While
there was no significant difference in the median hospital
stay for recanalization (9 days for stent patients vs. 9.5 days
for PTCA alone), the larger number of revascularization
procedures in the stent group resulted in a significantly
shorter stay at follow-up: median three days compared with
seven days in the PTCA group.
Risk factors for restenosis and reocclusion. By univariate
analysis, two biologically linked variables emerged as statis-
tical risk factors for restenosis: recanalization of the right
coronary artery versus the left coronary artery (p 5 0.03) and
a previous posterior myocardial infarction versus a previous
anterior myocardial infarction (p 5 0.01). Diabetes mellitus
was the only cardiovascular risk factor more frequent in the
restenosis group, and all diabetics in the PTCA group had
restenosis. Multivariate regression analysis did not reveal a
significant independent risk factor for restenosis.
Multivariate significant risk factors for reocclusion were a
lower CCS angina class before recanalization (p 5 0.03)
and less residual stenosis after recanalization (p 5 0.04;
significance of the logistic model p 5 0.004).
Figure 3. Analysis according to treatment. Stent implantation
resulted in a significant rightward shift of the MLD distribution
indicating a larger lumen both at the end of the procedure (top)
and at six-months follow-up (bottom).
Figure 4. Analysis by intention to treat. Even by including the
seven crossover patients with stenting against randomization into
the PTCA group, the effect of elective stent implantation after
recanalization of chronic total occlusions remained obvious.
Table 3. Events and Clinical data
Events
All
Patients PTCA Stent
p
Value
Death (cardiac) 0 0 0 —
Myocardial infarction 0 0 0 —
Bypass surgery 3 (3.8%) 2 (5%) 1 (2.5%) NS
New/recurrent
(un)stable angina
13 (16.3%) 9 (22.5%) 4 (10%) NS
PTCA repeated 26 (32.5%) 16 (40%) 10 (25%) NS
Event-free patients 46 (57.5%) 18 (45%) 28 (70%) 0.024
n 5 80. Stent implantation resulted in a significant reduction of new onset of angina
and repeated revascularization, analysis by intention to treat. PTCA 5 percutaneous
transluminal coronary angioplasty.
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Meta-analysis with three other controlled trials. Re-
cently, three similar trials were published showing a signif-
icant benefit of the Palmaz-Schatz stent after recanalization
of chronic coronary occlusions: Gruppo Italiano di Studio
sullo Stent Nelle Occlusioni Coronariche (GISSOC) (11),
Stenting in Chronic Coronary Occlusion (SICCO) (9) and
Mori et al. (10). Despite the usage of different stents and the
fact that the three other trials also included nontotal
occlusions (TIMI 1), it seems to be reasonable to combine
the results of all three studies in order to achieve a more
general conclusion about stent implantation after recanali-
zation of chronic total occlusions. All three studies showed
a convincing correspondence: in this collective of 374
patients, the stent implantation reduced restenosis and
reocclusion rate by more than 50% (Table 4), and the stent
group had a larger vessel lumen both directly after procedure
and after six months compared with the PTCA group
(Table 5).
In terms of basic patient data, there are three significant
differences between GISSOC, SICCO, the trial from Mori
et al. (10) and the present (SPACTO) study: there were
more women in SPACTO compared with GISSOC,
SICCO and Mori et al. (10) (30.6% female patients vs.
15.5%, 17.9% and 14.6%; p , 0.01). In SICCO, 74.4% of
the patients had an occlusion existing longer than 3 months,
compared with 38.8% in SPACTO and 36.5% in the trial of
Mori et al. (10). In the Mori Study and the GISSOC trial,
most (58.3%, and 52.7%) of the occlusions were located in
the LAD compared with 41.9% LAD occlusions in SICCO
and 31.8% in SPACTO, respectively.
DISCUSSION
Stenting has become very popular in combination with
almost all angioplasty procedures, but there are only few
indications based on randomized trials [proximal focal LAD
stenoses (7,8) saphenous vein graft lesions (15), bail-out-
stenting].
The aim of this study was to examine whether there is an
advantage of elective Wiktor stent implantation after re-
opening of chronic total occlusions. Similar to the results of
STRESS (7) and BENESTENT (8) for focal nonocclusive
lesions, we found a significant and even greater reduction of
restenosis, and remarkably of reocclusions, in the stent
group compared with PTCA alone. The difference was
mainly due to the stent’s ability to provide and maintain a
greater postprocedural lumen. This angiographical improve-
ment was translated into a better clinical outcome of the
stent patients with fewer recurrences of symptoms and
reinterventions after six months.
Risk factors for restenosis and reocclusion. There was no
independent risk factor for restenosis beside treatment with
stent or PTCA. The higher incidence of restenoses in the
RCA is probably due to minor distribution differences
including the greater length of the stented segments in the
RCA. Correspondingly, the patients with restenosis had
more likely posterior than anterior previous myocardial
infarction.
Risk factors for reocclusion in our study were a lower
angina class before the intervention and less residual stenosis
after recanalization. Yet, this is a small subgroup, and
almost all reocclusions (eight out of nine) occurred in the
balloon group, which had a trend towards a lower angina
class at baseline. A biological explanation could be a better
collateral flow reflected by the lower angina before recana-
lization and resulting in concurrent blood flow after reopen-
ing of the vessel. The lower residual stenosis as a statistical
risk factor for reocclusion might occur by chance. However,
because we tried to avoid crossovers from the balloon to the
Figure 5. Angina class. Patients with stents had a significantly
greater improvement of their CCS class (1.3 vs. 0.3 classes; p ,
0.01). The PTCA group had a slightly lower anginal class pre
procedure (2.0 vs 2.5, p 5 0.04).
Table 4. Pooled End Points of the Four Stenting for Chronic Occlusion Trials SPACTO, SICCO (9), Mori et al. (10) and
GISSOC (11), analysis by intention to treat
n
Restenosis Reocclusions
PTCA Stent p Value PTCA Stent p Value
Sirnes et al. (9) 114 42 (73.7%) 18 (31.6%) , 0.001 15 (26.3%) 7 (12.3%) NS
Mori et al. (10) 96 30 (56.6%) 12 (27.9%) 0.005 6 (11.3%) 3 (7.0%) 0.040
Rubartelli et al. (11) 97 32 (68.1%) 16 (32.0%) , 0.001 16 (34.0%) 4 (8.0%) 0.002
SPACTO 67 21 (63.6%) 11 (32.4%) 0.010 8 (24.2%) 1 (2.9%) 0.011
Pooled 374 125 (65.8%) 57 (31.0%) , 0.001 45 (23.7%) 15 (8.2%) , 0.001
Patients (408) were randomized and 374 had angiographic follow-up (92%).
PTCA 5 percutaneous transluminal coronary angioplasty.
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stent group, a higher mechanical vessel wall damage in
patients with less residual stenosis cannot be excluded.
Comparison with other stent trials. In contrast to find-
ings of elective stenting of stenoses (e.g., BENESTENT),
we found no significant increase in late lumen loss of the
stent group in this trial. A possible explanation is that
intimal proliferation after recanalization of chronic total
occlusions is already activated to a maximum level (as
indicated by the high restenosis rate after conventional
balloon recanalization), so that stent implantation does not
result in any further substantial activation. Furthermore, the
larger lumen maintained by the stent leads to a better flow
and an increase in vessel wall shear stress, which inhibits
intimal proliferation (16) and might foster endothelializa-
tion by inhibiting endothelial apoptosis (17).
Study limitations. A potential limitation of our study is
the small sample size. The same is true for the three other
randomized trials dealing with stents in chronic occlusions
(9–11). Yet, all the four studies, SICCO, Mori et al. (10)
and GISSOC, and now SPACTO, showed convincingly
parallel results. Combining them into a meta-analysis of 374
patients shows a conclusive advantage of elective stent
implantation after recanalization of chronic total occlusions.
All three studies are limited to one certain stent type. Due
to the small sample size, we did not try to perform a
comparison of the stents.
The major advantages of the Wiktor stent are its excellent
visibility, the high flexibility and the easy access to small
branch vessels through the stent wire loops (18). On the
other hand, the low surface covered by the stent represents
a disadvantage in irregular lesions with protruding dissec-
tional flaps (19). Despite the low mass of the stent, it is
sufficiently resistant to the collapsing pressure of a coronary
segment (20,21). In the present study, we found that
Wiktor stent implantation is easy to perform, including
crossing of the stent by another stent, and had a low rate of
stent thrombosis or other complications.
Due to our study design, the evidence of a positive effect
of elective stent implantation after recanalization of chronic
total occlusions is limited to vessels .2.5 mm. Other studies
(22,23) demonstrated a higher stent restenosis rate in
smaller vessels, so that there might be no benefit of stent
implantation after recanalization of total occlusions in very
small vessels.
Summary and conclusion. Primary implantation of the
Wiktor stent after recanalization of chronic total occlusions
resulted in a significant reduction of the restenosis and
reocclusion rate, as well as a reduction of repeated PTCA
and a new onset of unstable angina. In terms of angio-
graphical data, elective stenting resulted in a significantly
larger vessel lumen both acutely and at six months follow-
up. The better angiographic result corresponded to a better
clinical outcome of the stent patients with less recurrence of
symptoms and reinterventions after six months.Ta
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In contrast to other stent applications, stenting of chronic
total occlusions is not associated with an increased late
lumen loss.
Based on the pooled data from this trial with the results
of SICCO, Mori et al. (10) and GISSOC, we conclude that
elective stenting after recanalization of a chronic total
occlusion improves the angiographic and clinical outcome
and thus represents a proven stent indication.
Reprint requests and correspondence: Dr. Martin Ho¨her, De-
partment of Cardiology, University of Ulm, Robert-Koch-Strabe 8,
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